Previous close | 0.7500 |
Open | 0.7500 |
Bid | 0.0100 |
Ask | 0.1600 |
Strike | 105.00 |
Expiry date | 2024-01-19 |
Day's range | 0.7500 - 0.7500 |
Contract range | N/A |
Volume | |
Open interest | 4.58k |
FOSTER CITY, Calif., November 30, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced it will present new data at San Antonio Breast Cancer Symposium (SABCS) 2023, supporting the use of Trodelvy® (sacituzumab govitecan-hziy) in certain metastatic triple-negative breast cancer (mTNBC) and pre-treated HR+/HER2- metastatic breast cancer (mBC) patients.
These stocks aren't popular on the market right now, but investors shouldn't let that scare them off.
Pfizer and Amazon Web Services are just another example of how artificial intelligence is working in the background in healthcare.